iTeos Therapeutics, Inc. - Common Stock (ITOS)

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended.

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.

iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.

The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.

In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments that defied the trend by moving lower.

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

ITOS stock results show that ITeos Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.